The App4Independence (A4i) is a Joint Venture between the Centre for Addiction and Mental Health (CAMH) and MEMOTEXT. A4i is a patent pending, validated, digital therapeutic with a regulatory pathway for complex behavioural health. A4i’s premier indication is to provide support, isolation-reduction and relapse-risk identification in schizophrenia/psychosis spectrum illnesses. Through research, development and user co-design, A4i has developed a portal/EMR solution and mobile application. Demonstrating significant outcomes with patients and traction with Canadian and US providers and academic health science centers, CAMH schizophrenia services have engaged in using A4i in routine care.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
A4i for Schizophrenia/Psychosis
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):